Epilepsy with Myoclonic Atonic Seizures
ICD-10 G40.4 · ICD-11 8A61.2Y.2

What Is the First-Line Treatment for Epilepsy with Myoclonic Atonic Seizures?

Epilepsy with myoclonic atonic seizures (ICD-10 G40.4, ICD-11 8A61.2Y.2) is a defined epilepsy syndrome requiring careful first-line selection. Published paediatric data show that a substantial proportion of patients do not achieve adequate control with the first treatment attempted, making evidence-based agent choice a priority from the outset.

Clinical Goals

The primary targets are a greater than 50% reduction in seizure frequency (treatment response) and, where achievable, complete seizure freedom.

First-Line Approach

First-line management is built around antiseizure medication. Paediatric research consortium data and international Delphi consensus identify a primary recommended agent along with recognised alternative first-line options — each suited to different clinical contexts.

The specific agents, decision points, and full sequencing are available in the complete structured regimen below.

Instant Access to Structured Evidence-Based Regimens

References

  1. According to the Paediatric Epilepsy Research Consortium survey, valproate is the only recommended first-line therapy for epilepsy with myoclonic-atonic seizures.
  2. An international Delphi consensus endorsed valproate and clobazam as first-line treatments, with the ketogenic diet identified as the optimal second-line treatment.
  3. Clonazepam was also considered a first-line option, whereas ethosuximide was strongly recommended as second-line therapy.
  4. A retrospective analysis of 166 children with epilepsy with myoclonic-atonic seizures found that only 26% responded to the first three antiseizure medications, defined as a greater than 50% seizure reduction.
View source ↗